Skip to main content
. 2024 Sep 29;17(10):1299. doi: 10.3390/ph17101299
AEMPS Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Medical Devices)
AKI acute kidney injury
AOR adjusted odds ratio
BIFAP Base de datos para la Investigación Farmacoepidemiológica en el Ámbito Público
CI confidence interval
CKD chronic kidney disease
CKD-EPI chronic kidney disease epidemiology collaboration
CKI chronic kidney insufficiency
COVID-19 coronavirus disease 2019
eGFR estimated glomerular filtration rate
GLD glucose-lowering drug
GLP-1 RA glucagon-like peptide 1 receptor agonist
IQR interquartile range
KDIGO kidney disease improving global outcomes
OR odds ratio
PAD peripheral artery disease
SGLT-2i Sodium–glucose cotransporter-2 inhibitors
TIA transient ischemic attack
T2DM type 2 diabetes mellitus